Medidata, a Dassault Systèmes brand, and Bioforum are strengthening their decade-long partnership to improve clinical data and biometric solutions for clinical trials. The expanded collaboration aims to provide Bioforum’s clients with high-quality, efficient data services through Medidata's Clinical Data Studio and AI-driven biometrics.
Enhanced Technology for Agile Clinical Development
Bioforum's biotech customers will now have broader access to Medidata’s AI-powered technology, fostering a more agile clinical development process. In addition to leveraging Medidata Rave EDC and Medidata Rave RTSM, which have supported 60 Bioforum studies across various therapeutic areas, Bioforum is incorporating Medidata Clinical Data Studio and Medidata eConsent.
Streamlining Data and Ensuring Compliance
The integration of Medidata Clinical Data Studio and eConsent is expected to streamline data flow, maintain data integrity, and ensure compliance. These tools are designed to help sponsors manage clinical data in a secure and accurate manner, ready for analysis.
Executive Perspectives
Amir Malka, CEO and co-founder of Bioforum, stated, “With our team of experts, industry-leading biometric services, and proprietary technology, Bioforum empowers sponsors to seamlessly manage their clinical data in one place and ensure it’s secure, accurate, and ready for analysis. We’re excited to be strengthening our alliance with Medidata and, together, providing our customers with the adaptability and advanced solutions they need to thrive.”
Janet Butler, executive vice president, head of global sales, Medidata, added, “Our expanded partnership with Bioforum brings AI-driven clinical trial management to agile biotech start-ups, accelerating their path to market. By harnessing our Patient Data Surveillance and RBQM platforms, we’re delivering improved operational efficiency for Bioforum and seamless, high-quality data access for their clients.”
Upcoming Sponsorship
Bioforum will sponsor Medidata’s NEXT New York, a clinical trials conference scheduled for November 13 to 14 in New York City.
